|
See related Faslodex inj information |
|
|
|
Manufacturer |
AstraZeneca |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Fulvestrant |
|
Indications |
Postmenopausal women w/ oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy w/ an antioestrogen.
Click to view Faslodex detailed prescribing infomation |
|
Dosage |
Adult female (including elderly) Initially 500 mg slow IM at 1 mth intervals w/ an additional 500 mg 2 wk after.
Click to view Faslodex detailed prescribing infomation |
|
Overdosage |
View Faslodex overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Severe hepatic impairment, pregnancy, lactation.
Click to view Faslodex detailed prescribing infomation |
|
Special Precautions |
Mild to moderate hepatic impairment, severe renal impairment (CrCl <30 mL/min). Patients w/ bleeding diatheses, thrombocytopenia or those taking anticoagulants. Thrombolic events in women w/ advanced breast cancer. Potential risk of osteoporosis. Childn & adolescents.
Click to view Faslodex detailed prescribing infomation |
|
Adverse Drug Reactions |
Nausea, asthenia, inj site reactions, elevated liver enzymes (ALT, AST, ALP).
View ADR Monitoring Form |
|
Drug Interactions |
[Click for Faslodex detailed prescribing infomation]
View more drug interactions with Faslodex |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Faslodex storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Faslodex description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Faslodex mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
